Rehan Verjee, Precede Biosciences CEO

BMS-backed liq­uid biop­sy biotech Pre­cede Bio­sciences de­buts to en­hance pre­ci­sion med­i­cine ap­proach­es

Pre­cede Bio­sciences has emerged with a liq­uid biop­sy plat­form that can il­lu­mi­nate a pa­tient’s bi­o­log­i­cal state and would serve as the foun­da­tion for blood tests to help drug­mak­ers build a pic­ture of pa­tients like­ly to re­spond to treat­ments.

Many pre­ci­sion med­i­cine ef­forts have fo­cused on gene mu­ta­tions, but the Boston, MA-based com­pa­ny has a broad­er ap­proach. “There are so many oth­er con­texts that are non-mu­ta­tion­al­ly dri­ven. Where there’s a [non-mu­ta­tion­al] mol­e­c­u­lar mech­a­nism un­der­ly­ing the dis­ease… we’re fo­cused on ad­dress­ing those,” CEO Re­han Ver­jee told End­points News in an in­ter­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.